Chromadex Corp
NASDAQ:CDXC
Relative Value
The Relative Value of one CDXC stock under the Base Case scenario is 3.35 USD. Compared to the current market price of 3.47 USD, Chromadex Corp is Overvalued by 3%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
CDXC Competitors Multiples
Chromadex Corp Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Chromadex Corp
NASDAQ:CDXC
|
260.2m USD | 3.1 | -52.7 | -51 | -41.6 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
221.6B USD | 5.2 | 37 | 22.8 | 33.5 | ||
US |
Danaher Corp
NYSE:DHR
|
181.8B USD | 7.6 | 38.3 | 25.9 | 36.5 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
42.6B USD | 2.8 | 31.4 | 17 | 26.2 | ||
CH |
Lonza Group AG
SIX:LONN
|
37.9B CHF | 5.6 | 57.9 | 19.9 | 29.2 | ||
US |
Agilent Technologies Inc
NYSE:A
|
40.3B USD | 6 | 32.6 | 26.1 | 31.3 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
54.8T KRW | 14.8 | 63.9 | 33.7 | 48.5 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
26.8B USD | 7.1 | 34 | 23.8 | 26.4 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
26.8B USD | 9.1 | 45.2 | 30.9 | 36.9 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
25.4B USD | 3.1 | 41.4 | 17.6 | 27.4 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
18.9B EUR | 7 | 74.2 | 32 | 52.5 |